洛铂胸腔灌注联合艾迪注射液治疗恶性胸腔积液的临床分析及其对血清VEGF的影响

摘要

Objective To evaluate the treatment effect of Lobaplatin combined with Aidi Injection on patients with advanced NSCLC, and observe the influence on the level of serum VEGF by the treatment. Methods 60 patients, with advanced NSCLC and malignant pleural effusion, were divided into two groups (observation group and control group) randomly, with 30 cases in each group. All patients were treated with thoracentesis and inserted central venous catheter for the drainage of pleural effusion. After exhaustion of pleural effusion, the control group was treated with Lobaplatin by pleural perfusion, and the observation group was treated with Aidi Injection in addition to the treatment on control group. The treatment, side effects and quality of life and the level of serum VEGF were compared. Results After treatment, it is significant that clinical effects, side effect and KPS score of living quality of the observation group was better than that of the control group (P<0.05). The level of serum VEGF was significant lower than that before treatment in both groups (P<0.05). The decrease of VEGF serum level in the observation group was significantly lower than the decrease in the control group (P <0.05). Conclusion Lobaplatin combined with Aidi Injection was one of the effective method for the treatment of NSCLS with malignant pleural effusion, and was worthy of clinical application.%目的：评价洛铂胸腔灌注联合艾迪注射液治疗晚期非小细胞肺癌（NSCLC）患者恶性胸腔积液的治疗效果并观察其对血清血管内皮生长因子（VEGF）的影响。方法：将60例晚期NSCLC伴恶性胸腔积液的患者随机分为观察组（30例）和对照组（30例），两组均采用胸腔穿刺术置入中心静脉导管引流胸腔积液，待排尽胸腔积液后，对照组给予洛铂胸腔灌注，观察组在对照组的基础上给予艾迪注射液静脉注射，比较两组临床疗效、不良反应、生活质量改善情况以及血清VEGF水平的变化。结果：两组患者完成治疗疗程后，观察组患者的临床疗效、不良反应、生活质量KPS评分均明显优于对照组（P＜0．05）；两组患者治疗后血清VEGF水平均明显低于治疗前（P＜0．05），且观察组VEGF水平下降更为明显，与对照组相比差异有统计学意义（P＜0．05）。结论：洛铂胸腔灌注联合艾迪注射液是其中一种有效治疗NSCLC恶性胸腔积液的方法，值得临床推广。